The rationale for targeting TGF-β in chronic liver diseases.

Gianluigi GiannelliWolfgang MikulitsSteven DooleyIsabel FabregatAristidis MoustakasPeter ten DijkePiero PortincasaPeter WinterRichard JanssenStefano LeporattiBlanca HerreraAranzazu Sanchez

Published in: European journal of clinical investigation (2016)

The identification of new TGF-β related biomarkers will help to select those patients most likely to benefit from therapy aimed at inhibiting the TGF-β pathway. New formulations that may provide a more controlled and sustained delivery of the drug will improve the therapeutic success of such treatments.

Keyphrases

transforming growth factor
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
signaling pathway
clinical trial
peritoneal dialysis
prognostic factors
epithelial mesenchymal transition
stem cells
cancer therapy
drug delivery
adverse drug